Arcutis Biotherapeutics, Inc.
Congress has disclosed 3 buys and 2 sells of ARQT (Arcutis Biotherapeutics, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
5 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | BUY ◆ insider divergence | Self · 150 Main Street Trust > Bank of America | 2026-05-29 | 7 days | -1.1% | $1K–$15K 0.1% of NW |
32.9 | ↗ filing |
| Gilbert Cisneros | House | SELL ◆ insider convergence · moderate | Self · 150 Main Street Trust > Bank of America | 2025-12-11 | 29 days | -4.2% | $1K–$15K 0.1% of NW |
64.1 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-09-15 | 26 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Josh Gottheimer | House | BUY ◆ insider convergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-04-17 | 16 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-06-15 | 23 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in ARQT — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in ARQT, 3 coincided with corporate insiders moving the same way within 60 days, and 1 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-15 | Welgus Howard G. | Director | SELL 10b5-1 | $127K | ↗ EDGAR |
| 2026-09-16 | Matsuda Masaru | Other | SELL 10b5-1 | $92K | ↗ EDGAR |
| 2026-09-15 | Welgus Howard G. | Director | SELL 10b5-1 | $114K | ↗ EDGAR |
| 2026-09-08 | Matsuda Masaru | Other | SELL 10b5-1 | $250K | ↗ EDGAR |
| 2026-08-27 | Curran Terrie | Director | SELL | $279K | ↗ EDGAR |
| 2026-08-27 | Curran Terrie | Director | SELL | $677K | ↗ EDGAR |
| 2026-08-20 | Curran Terrie | Director | SELL | $28K | ↗ EDGAR |
| 2026-08-19 | Burnett Patrick | Other | SELL | $46K | ↗ EDGAR |
| 2026-08-17 | Welgus Howard G. | Director | SELL 10b5-1 | $124K | ↗ EDGAR |
| 2026-08-12 | Burnett Patrick | Other | SELL | $175K | ↗ EDGAR |
| 2026-08-11 | Burnett Patrick | Other | SELL | $220K | ↗ EDGAR |
| 2026-08-03 | Watanabe Todd | Director | SELL 10b5-1 | $114K | ↗ EDGAR |
| 2026-08-03 | Matsuda Masaru | Other | SELL 10b5-1 | $32K | ↗ EDGAR |
| 2026-08-03 | Burnett Patrick | Other | SELL 10b5-1 | $25K | ↗ EDGAR |
| 2026-07-15 | Welgus Howard G. | Director | SELL 10b5-1 | $127K | ↗ EDGAR |
| 2026-06-17 | Welgus Howard G. | Director | SELL 10b5-1 | $16K | ↗ EDGAR |
| 2026-06-15 | Welgus Howard G. | Director | SELL 10b5-1 | $100K | ↗ EDGAR |
| 2026-06-15 | LIN SUE-JEAN | Director | SELL 10b5-1 | $121K | ↗ EDGAR |
| 2026-05-11 | Burnett Patrick | Other | SELL 10b5-1 | $5K | ↗ EDGAR |
| 2026-05-11 | Vairavan Latha | C-suite | SELL 10b5-1 | $9K | ↗ EDGAR |
| 2026-05-04 | Burnett Patrick | Other | SELL 10b5-1 | $16K | ↗ EDGAR |
| 2026-05-04 | Matsuda Masaru | Other | SELL 10b5-1 | $172K | ↗ EDGAR |
| 2026-05-04 | Matsuda Masaru | Other | SELL 10b5-1 | $21K | ↗ EDGAR |
| 2026-05-04 | Watanabe Todd | Director | SELL 10b5-1 | $75K | ↗ EDGAR |
| 2026-05-04 | Vairavan Latha | C-suite | SELL 10b5-1 | $32K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-15 | Welgus Howard G. Director 10b5-1 | SELL | $127K |
| ◆ insider | 2026-09-16 | Matsuda Masaru Other 10b5-1 | SELL | $92K |
| ◆ insider | 2026-09-15 | Welgus Howard G. Director 10b5-1 | SELL | $114K |
| ◆ insider | 2026-09-08 | Matsuda Masaru Other 10b5-1 | SELL | $250K |
| ◆ insider | 2026-08-27 | Curran Terrie Director | SELL | $279K |
| ◆ insider | 2026-08-27 | Curran Terrie Director | SELL | $677K |
| ◆ insider | 2026-08-20 | Curran Terrie Director | SELL | $28K |
| ◆ insider | 2026-08-19 | Burnett Patrick Other | SELL | $46K |
| ◆ insider | 2026-08-17 | Welgus Howard G. Director 10b5-1 | SELL | $124K |
| ◆ insider | 2026-08-12 | Burnett Patrick Other | SELL | $175K |
| ◆ insider | 2026-08-11 | Burnett Patrick Other | SELL | $220K |
| ◆ insider | 2026-08-03 | Watanabe Todd Director 10b5-1 | SELL | $114K |
| ◆ insider | 2026-08-03 | Matsuda Masaru Other 10b5-1 | SELL | $32K |
| ◆ insider | 2026-08-03 | Burnett Patrick Other 10b5-1 | SELL | $25K |
| ◆ insider | 2026-07-15 | Welgus Howard G. Director 10b5-1 | SELL | $127K |
| ◆ insider | 2026-06-17 | Welgus Howard G. Director 10b5-1 | SELL | $16K |
| ◆ insider | 2026-06-15 | Welgus Howard G. Director 10b5-1 | SELL | $100K |
| ◆ insider | 2026-06-15 | LIN SUE-JEAN Director 10b5-1 | SELL | $121K |
| Congress | 2026-05-29 | Gilbert Cisneros | BUY | $1K–$15K |
| ◆ insider | 2026-05-11 | Burnett Patrick Other 10b5-1 | SELL | $5K |
| ◆ insider | 2026-05-11 | Vairavan Latha C-suite 10b5-1 | SELL | $9K |
| ◆ insider | 2026-05-04 | Burnett Patrick Other 10b5-1 | SELL | $16K |
| ◆ insider | 2026-05-04 | Matsuda Masaru Other 10b5-1 | SELL | $172K |
| ◆ insider | 2026-05-04 | Matsuda Masaru Other 10b5-1 | SELL | $21K |
FAQ Common questions
How much has Congress traded ARQT?
3 disclosed buys and 2 sells of ARQT (Arcutis Biotherapeutics, Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade ARQT?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.